SFE Investment Counsel Has $3.46 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

SFE Investment Counsel boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,629 shares of the medical research company’s stock after acquiring an additional 690 shares during the period. SFE Investment Counsel’s holdings in IQVIA were worth $3,464,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IQV. FMR LLC raised its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc lifted its holdings in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the period. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after acquiring an additional 39,772 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 1.6 %

IQV stock opened at $197.64 on Thursday. The business has a fifty day moving average of $200.66 and a 200-day moving average of $218.67. The company has a market cap of $35.87 billion, a P/E ratio of 26.35, a PEG ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IQV. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday. Deutsche Bank Aktiengesellschaft cut their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.